Endocrinologists’ process for determining which oral type 2 diabetes medicine to prescribe involves understanding each treatment’s efficacy, safety, and tolerability, among other clinical attributes. Oral Type 2 Diabetes Rational Brand Perceptions provides physicians’ rankings of the best diabetes medicine for type 2 patients.
The rational basis for prescribing any oral type 2 diabetes treatment hinges on an endocrinologist’s perceptions of how the drug will work for the individual patient. This strategy guide offers a quantitative assessment of type 2 diabetes brand perceptions to assist commercial executives in understanding how to properly position their drugs and communicate to endocrinologists and primary care providers which clinical attributes make their brand superior.
The guide provides a detailed examination of which oral type 2 diabetes brands are most effective, which are the safest and, in short, which is the best diabetes medicine for type 2 patients. Additionally, this information details endocrinologists’ perceptions of each existing oral type 2 diabetes brand’s strengths and weaknesses.
Overview of Oral Type 2 Diabetes Rational Brand Perceptions
As endocrinologists evaluate their options to treat type 2 diabetes, they need to weigh each drug’s strengths and weaknesses to determine which brand is the best diabetes medicine for type 2 patients. The data and analysis shared in this report illustrate how each type 2 diabetes brand’s clinical attributes contribute to physicians’ perceptions of the drug.
The data in Oral Type 2 Diabetes Rational Brand Perceptions analyzes each brand’s critical clinical attributes:
- Efficacy
- Safety
- Dosing
- Tolerability
- Access
- Support
Branded Treatments Analyzed
- Jardiance
- Metformin
- Rybelsus
- Farxiga
- Invokana
- Tradjenta
- Steglatro
- Januvia
- Onglyza
- Thiazolidinediones TZDs
- Sulfonylureas
Strategic Questions Answered about Oral Type 2 Diabetes Rational Brand Perceptions
- Clinical Perceptions: How do physicians perceive current oral type 2 diabetes brands in terms of their efficacy, safety, dosing, tolerability, access, and support?
- Brand Ownership: Which oral type 2 diabetes brands are perceived to be best vs. worst across efficacy, safety, dosing, tolerability, access, and support?
- Attribute Importance: Which clinical product attributes are most important to physicians when choosing the best diabetes medicine for type 2 patients?
Summary of Strategic Insights Contained in Oral Type 2 Diabetes Rational Brand Perceptions
- HCPs have positive perceptions of Farxiga (dapagliflozin) being a well-rounded medication. As expected, the only strong weakness is in access.
- HCPs generally do not have strong perceptions of Onglyza/ Kombiglyze (saxagliptin) one way or another. It is rarely ranked highly in strength or weakness.
- Rybelsus (semaglutide) is perceived as having strong efficacy among endocrinologists. However, primary care providers are less likely to state efficacy as a strength.
Benefits of Purchasing Oral Type 2 Diabetes Rational Brand Perceptions
- Cost-efficient data on HCPs’ oral type 2 diabetes brand perceptions to support your commercial strategy decisions.
- Oral type 2 diabetes brand perceptions and insights drawn from in-depth interviews among US KOLs and surveys of more than 155 endocrinologists
- A complimentary 30-minute workshop with you (and your team)
- Unlimited support from Vivisum’s type 2 diabetes strategist for 1-year.
Table of Contents
Executive Summary – 5
Research Methodology: Robust Insights from US Endocrinologists – 6
The Strategic Six: Key Insights About Rational Perceptions of Type 2 Diabetes Brands – 7
T2D Clinical Brand Perception Winners – 8
T2D Clinical Brand Perception Landscape – 9
Oral Type 2 Diabetes Clinical Brand Attributes – 10
Most Ideal Type 2 Diabetes Brands – 11
Least Ideal Type 2 Diabetes Brands – 12
Most Efficacious Type 2 Diabetes Brands – 13
Least Efficacious Type 2 Diabetes Brands – 14
Most Favorable Safety Profile Among T2D Brands – 15
Least Favorable Safety Profile Among T2D Brands – 16
Easiest Dosing Among T2D Brands – 17
Most Challenging Dosing Among T2D Brands – 18
Best Tolerability Among Type 2 Diabetes Brands – 19
Worst Tolerability Among Type 2 Diabetes Brands – 20
Best Access Among Type 2 Diabetes Brands – 21
Worst Access Among Type 2 Diabetes Brands – 22
Best Support Among Type 2 Diabetes Brands – 23
Worst Support Among Type 2 Diabetes Brands – 24
Type 2 Diabetes Brand Profiles – 25
Jardiance Brand Profile – 26
- Jardiance Most/Least Ideal – 27
- Jardiance Strengths – 28
- Jardiance Weaknesses – 29
- Jardiance Summary – 30
Rybelsus Brand Profile – 31
- Rybelsus Most/Least Ideal – 32
- Rybelsus Strengths – 33
- Rybelsus Weaknesses – 34
- Rybelsus Summary – 35
Farxiga Brand Profile – 36
- Farxiga Most/Least Ideal – 37
- Farxiga Strengths – 38
- Farxiga Weaknesses – 39
- Farxiga Summary – 40
Januvia Brand Profile – 41
- Januvia Most/Least Ideal – 42
- Januvia Strengths – 43
- Januvia Weaknesses – 44
- Januvia Summary – 45
Invokana Brand Profile – 46
- Invokana Most/Least Ideal – 47
- Invokana Strengths – 48
- Invokana Weaknesses – 49
- Invokana Summary – 50
Tradjenta Brand Profile – 51
- Tradjenta Most/Least Ideal – 52
- Tradjenta Strengths – 53
- Tradjenta Weaknesses – 54
- Tradjenta Summary – 55
Steglatro Brand Profile – 56
- Steglatro Most/Least Ideal – 57
- Steglatro Strengths – 58
- Steglatro Weaknesses – 59
- Steglatro Summary – 60
Onglyza Brand Profile – 61
- Onglyza Most/Least Ideal – 62
- Onglyza Strengths – 63
- Onglyza Weaknesses – 64
- Onglyza Summary – 65
Attribute Importance & Brand Ownership – 66
Importance Attributes in Rx Decisions – 67
- Efficacy Importance Rank – 68
- Safety Importance Rank – 69
- Access Importance Rank – 70
- Tolerability Importance Rank – 71
- Dosing Importance Rank – 72
- Support Importance Rank – 73
Contact – 74
